AbbVie Must Pay $3 Million in Retrial of First AndroGel Bellwether Suit

In a retrial, a jury ordered AbbVie to pay more than $3 million to a plaintiff who blamed his heart attack on misrepresentation of the risks posed by AbbVie’s testosterone replacement drug AndroGel.
Source: Drug Industry Daily